RxDoctor Payments Data

Lara Durna

Hematology & Oncology · Harbor City, CANPI 1962579706

Payments from drug & device makers

What this record shows

That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.

$24in general payments, 2019–2025

Across 2 payments — averaging $12.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merge Healthcare Incorporated$12
  • Gilead$12
$2,155,512in research payments, 2019–2025

Across 132 payments — averaging $16,330 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$775K
  • Genentech, Inc.$545K
  • AstraZeneca$422K
  • Daiichi Sankyo Inc.$213K
  • Eli Lilly$101K
  • Gilead$39K
  • plus $62K from 3 others

What the payments were for

  • Food & beverage$1250%
  • Education$1250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merge Healthcare Incorporated1$12
Gilead1$12

How this compares

$24 in reported general payments places this provider in the 5th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Most prescribed under Part D

DrugClaimsCost to plans & patients
Anastrozole24$690

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Harbor City

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →